Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio

This article was originally published in Start Up

Executive Summary

Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?

Related Content

Lilly Tries to Buy Time
With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene
The A-List: 2008's Trend Shaping Series A Financings
Best of the Blog: IN VIVO, September 2008
The Alzheimer's Divide
A More Detailed Image of Alzheimer's Disease
Pacific Horizon: Encouraging Mutations in the Venture Model
Alzheimer's Disease Diagnostics
Zapaq Inc.
Addressing Alzheimer's


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts